Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

candidate is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. The NDA-filing process is ongoing and expected to be completed by the end of February 2008.

In December 2007, Arpida announced the enrolment and dosing of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal th
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... SAN DIEGO, March 3, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... patient care by developing novel medicines for the treatment of ... for the fourth quarter and year ended December 31, 2010. ... well-positioned to create value in the evolving HCV landscape," said ...
... 2011 Novavax, Inc. (Nasdaq: NVAX ) ... visit the company,s headquarters in Rockville, Maryland, on Monday, ... at up to $179 million. The Office of Biomedical ... of the Assistant Secretary for Preparedness and Response at ...
... Executive search firm Sanford Rose Associates® - Minneapolis ... engagement for Nordson Corporation: Lise W. Duran as General ... of biomaterial applicators used in a wide variety of ... years of experience in the medical device industry, having ...
Cached Biology Technology:Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 7Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 2Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 3Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 4Sanford Rose Associates® - Minneapolis Fills Key Management Position for the Micromedics Operation of Nordson Corporation 2
(Date:7/10/2014)... , July 7, 2014 Fingerprint Cards, ... major design win (DW). A Chinese Top 5 smartphone OEM ... start of mass production in October 2014.   ... Top 5 smartphone OEM, which has a planned date for ... target sales volume for this phone of 3 million units. ...
(Date:7/10/2014)... GOTHENBURG, Sweden , July 8, 2014 ... FPC1021 has won a new design win (DW). An Asian ... targeted date for mass production start in August 2014.   ... an Asian smartphone OEM, which has a planned date for ... received an initial ramp order of SEK 5M, for delivery ...
(Date:7/10/2014)... Ill. , July 9, 2014 ... (EHR), spurred in large part by meaningful use ... health care providers interact with laboratory information. Now, ... in the field of clinical informatics in order ... To address the educational needs of ...
Breaking Biology News(10 mins):FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical ... patients suffering from schizophrenia characterized by motor disorders. ... collaboration with the research team Mairena Martin at the ... clinical researchers of the Health Park Sant Joan de ...
... The Clinical Nutrition Research Centre (CNRC) -- a ... and Research (A*STAR) and National University Health Systems (NUHS) ... that will conduct nutritional studies to understand the causes ... develop products and formulate diets that can reduce the ...
... LAKE CITY, Utah, Jan. 29, 2014 Myriad Genetics, ... a clinical utility study with its Prolaris test, at ... Calif. The study demonstrated the significant clinical value ... prostate cancer. Prolaris is a prognostic test that ...
Cached Biology News:Identified a subgroup of schizophrenia patients with motor disorders 2Asia's first under-1-roof Nutritional Research Centre set up in Singapore 2Asia's first under-1-roof Nutritional Research Centre set up in Singapore 3Asia's first under-1-roof Nutritional Research Centre set up in Singapore 4Myriad's Prolaris significantly modifies treatment decisions for prostate cancer patients 2